Sativa Wellness Group plc (AQSE:SWEL) Executive Chairman Geremy Thomas caught up with DirectorsTalk to discuss the quality award at their facility in Poland, how this affects the novel foods accreditation and how he feels about David Beckham now being a competitor.
Q1: Today’s announcement about the quality award in Poland sounds pretty positive, what does it mean for Sativa Wellness Group?
A1: Well, last September, we completed a reverse takeover of a Canadian business called Stillcanna and they had a number of assets including this production facility in Poland.
So, we’ve invested further funds into developing that facility and today we’re announcing a quality award which indicates that investment and puts us on a firm path towards our goal of presenting to the market a seed to shelf CBD journey that the market can rely on.
Q2: Does this impact the novel foods accreditation you announced recently?
A2: I think it compliments it because the novel foods process run by the Food Standards Agency is all about quality compliance and certainly being able to demonstrate the credentials that we have in Poland helps with that process.
Q3: On a different note, David Beckham is now a competitor, howe do you feel about that?
A3: I think it’s great, I think we’ve seen a number of high profile new entrants to our market and that can only help. In ‘The Times’ today, there is an article calling for the government to appoint a medicinal cannabis tsar to oversee the further development of our marketplace here in the UK and we, at Sativa Wellness Group, support that.
